- Title
- A phase 3 trial of sebelipase alfa in lysosomal acid lipase deficiency
- Creator
- Burton, B. K.; Balwani, M.; Enns, G. M.; Erbe, R.; Ezgu, F.; Ficicioglu, C.; Furuya, K. N.; Kane, J.; Laukaitis, C.; Mengel, E.; Neilan, E. G.; Nightingale, S.; Feillet, F.; Peters, H.; Scarpa, M.; Schwab, K. O.; Smolka, V.; Valayannopoulos, V.; Wood, M.; Goodman, Z.; Yang, Y.; Eckert, S.; Rojas-Caro, S.; Barić, I.; Quinn, A. G.; Burrow, T. A.; Grande, C. Camarena; Coker, M.; Consuelo-Sánchez, A.; Deegan, P.; Di Rocco, M.
- Relation
- New England Journal of Medicine Vol. 373, Issue 11, p. 1010-1020
- Publisher Link
- http://dx.doi.org/10.1056/NEJMoa1501365
- Publisher
- Massachussetts Medical Society
- Resource Type
- journal article
- Date
- 2015
- Description
- Background: Lysosomal acid lipase is an essential lipid-metabolizing enzyme that breaks down endocytosed lipid particles and regulates lipid metabolism. We conducted a phase 3 trial of enzyme-replacement therapy in children and adults with lysosomal acid lipase deficiency, an underappreciated cause of cirrhosis and severe dyslipidemia. Methods: In this multicenter, randomized, double-blind, placebo-controlled study involving 66 patients, we evaluated the safety and effectiveness of enzyme-replacement therapy with sebelipase alfa (administered intravenously at a dose of 1 mg per kilogram of body weight every other week); the placebo-controlled phase of the study was 20 weeks long and was followed by open-label treatment for all patients. The primary end point was normalization of the alanine aminotransferase level. Secondary end points included additional disease-related efficacy assessments, safety, and side-effect profile. Results: Substantial disease burden at baseline included a very high level of low-density lipoprotein cholesterol (≥190 mg per deciliter) in 38 of 66 patients (58%) and cirrhosis in 10 of 32 patients (31%) who underwent biopsy. A total of 65 of the 66 patients who underwent randomization completed the double-blind portion of the trial and continued with open-label treatment. At 20 weeks, the alanine aminotransferase level was normal in 11 of 36 patients (31%) in the sebelipase alfa group and in 2 of 30 (7%) in the placebo group (P = 0.03), with mean changes from baseline of -58 U per liter versus -7 U per liter (P<0.001). With respect to prespecified key secondary efficacy end points, we observed improvements in lipid levels and reduction in hepatic fat content (P<0.001 for all comparisons, except P = 0.04 for triglycerides). The number of patients with adverse events was similar in the two groups; most events were mild and were considered by the investigator to be unrelated to treatment. Conclusions: Sebelipase alfa therapy resulted in a reduction in multiple disease-related hepatic and lipid abnormalities in children and adults with lysosomal acid lipase deficiency. (Funded by Synageva BioPharma and others; ARISE ClinicalTrials.gov number, NCT01757184.)
- Subject
- lysosomal acid lipase; lipid-metabolizing enzymes; randomised double-blind placebo controlled study
- Identifier
- http://hdl.handle.net/1959.13/1315023
- Identifier
- uon:22878
- Identifier
- ISSN:0028-4793
- Language
- eng
- Reviewed
- Hits: 14471
- Visitors: 14392
- Downloads: 0
| Thumbnail | File | Description | Size | Format |
|---|